# US 2026/0092281 A1 · Methods for treatment of anemia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0092281 A1
- Document ID: US20260092281A1
- Status: Published application
- Kind: A1
- Application number: 19/339,351
- Filed: 2025-09-25
- Published: 2026-04-02
- Earliest claimed: 2024-09-27
- Assignees: Dexcel Pharma Technologies Ltd.
- Applicants: Dexcel Pharma Technologies Ltd.
- Inventors: Nadav Marbach-Bar; Elena Feinstein; Noa Madar-Balakirski
- Web page: https://patentgrep.com/patent/US20260092281A1

## CPC

- C12N 15/1138: {against receptors or cell surface proteins}
- A61P 7/06: Antianaemics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C12N 15/1136: {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2310/317: with an inverted bond, e.g. a cap structure
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/343: having patterns, e.g. ==--==--==--
- C12N 2310/351: Conjugate
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are nucleic acids and compositions thereof for inhibiting expression of transferrin receptor 2 (TFR2). Also described are methods for treatment of TFR2-associated diseases, such as anemia, with the disclosed nucleic acids.

## Claims

### Claim 1

A method for treating a HAMP-related anemia, comprising:
administering to a subject in need thereof, an effective amount of a double-stranded nucleic acid comprising a sense strand and an antisense strand, wherein the sense strand comprises a sense strand sequence comprising:
5′-(C3)csgsguCfaUfAfCfugucgguuaa 3′ (SEQ ID NO: 308) and has three or four GalNAc moieties covalently attached to the 3′ end,
wherein the antisense strand comprises an antisense strand sequence comprising:
5′-(vinu)sUfsaacCf(3dG)AfCfaguaUfgAfccgsusc-3′ (SEQ ID NO: 293) or 5′-(vinu)sUfsaacCf(3dG)aCfaguaUfgAfccgsusc-3′ (SEQ ID NO: 297),
wherein a lowercase letter indicates a 2′-O-Methyl (2′-OMe) modified RNA nucleotide, an uppercase letter followed by f indicates a 2′-Fluoro (2′-F) modified RNA nucleotide, (C3) indicates a propanol or C3 alkyl moiety connected to the 5′ end of the strand via a phosphodiester linkage, s indicates a phosphorothioate linkage between adjacent nucleotides, (vinu) indicates a 5′ vinylphosphonate 2′-OMe RNA U nucleotide, and (3dG) indicates a G nucleotide in which ribose has H at the 3′ position, and is connected via a 2′-5′ bridge to a nucleotide following the G nucleotide,
thereby treating the anemia.

### Claim 2 (depends on 1)

The method of claim 1, wherein the three or four GalNAc moieties are covalently attached to the 3′ end of the sense strand via a triethyleneglycol (TEG) linker.

### Claim 3 (depends on 1)

The method of claim 1, wherein the sense strand sequence comprises:
5′-(C3)csgsguCfaUfAfCfugucgguuaasLsLsL-3 (SEQ ID NO: 291),
wherein a lowercase letter indicates a 2′-O-Methyl (2′-OMe) modified RNA nucleotide, an uppercase letter followed by f indicates a 2′-Fluoro (2′-F) modified RNA nucleotide, (C3) indicates a propanol or C3 alkyl moiety connected to the 5′ end of the strand via a phosphodiester linkage, s indicates a phosphorothioate linkage between adjacent nucleotides, and L indicates a monomer of N-acetylgalactosamine (GalNAc) with a TEG linker.

### Claim 4 (depends on 1)

The method of claim 1, wherein the HAMP-related anemia is an iron-refractory anemia, anemia of a chronic disease, or an anemia of inflammation.

### Claim 5 (depends on 1)

The method of claim 1, wherein the HAMP-related anemia is an anemia arising from cancer or cancer treatment.

### Claim 6 (depends on 5)

The method of claim 5, wherein the cancer is a solid tumor or advanced-stage cancer.

### Claim 7 (depends on 5)

The method of claim 5, wherein the cancer is a hematology-related cancer.

### Claim 8 (depends on 7)

The method of claim 7, wherein the hematology-related cancer is transfusion dependent myelofibrosis, transfusion independent myelofibrosis, multiple myeloma, Castelman disease, Hodgkin lymphoma, non-Hodgkin lymphoma, leukemia, myelodysplastic syndrome, myeloproliferative neoplasms, or Waldenstrom macroglobulinemia.

### Claim 9 (depends on 4)

The method of claim 4, wherein the anemia of inflammation is in a subject diagnosed with rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, scleroderma psoriatic arthritis, vasculitides, autoimmune thyroiditis, anti-neutrophil cytoplasmic antibody associated vasculitis, kryoglobulinemia, chronic kidney disease, chronic inflammation, obesity, metabolic syndrome, a chronic infection, chronic obstructive pulmonary disease, and chronic graft versus host disease.

### Claim 10 (depends on 1)

The method of claim 1, wherein the HAMP-related anemia arises from mutations in the TMPRSS6 gene.

### Claim 11 (depends on 1)

The method of claim 1, wherein the subject has a condition that results in overproduction or reduced elimination of hepcidin.

### Claim 12 (depends on 1)

The method of claim 1, wherein the subject is receiving or has previously received a treatment for anemia and is non- or poorly responsive to the treatment.

### Claim 13 (depends on 12)

The method of claim 12, wherein the double-stranded nucleic acid is administered to the subject, before, concurrently with, or following the treatment of anemia.
